LEXINGTON, Mass., March 4, 2016 /PRNewswire/ -- Pulmatrix, Inc., (NASDAQ: PULM) will present a business update at the Cowen and Company 36th Annual Health Care Conference on Wednesday, March 9th at 11:20 am EST (8:20 am PST). A live webcast of the presentation may be accessed in the investor relations section of the Company's website at www.pulmatrix.com. A replay of the presentation will be available on the Company's website for 90 days following the presentation.
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis (CF). In addition, Pulmatrix is pursuing opportunities in major pulmonary diseases through collaborations, including PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease (COPD). Pulmatrix's product candidates are based on iSPERSE™, its proprietary dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
SOURCE Pulmatrix, Inc.